Kali Stasi

Kali Stasi serves as the Chief Medical Officer at SparingVision since June 2025, where responsibilities include advancing the clinical strategy for the company's product portfolio and overseeing medical affairs and patient advocacy. Prior to this, Kali held the position of Consulting Principal at Innoviama LLC, specializing in due diligence and pharmaceutical development in ophthalmology and neurology. As a Co-Founder and Chief Medical Officer at Diorasis Therapeutics, Kali played a key role in developing a first-in-class gene therapy for glaucoma. Kali's experience also includes leading the clinical team at SalioGen Therapeutics and serving as Senior Vice President of Clinical Development at Adverum Biotechnologies. Educational qualifications include a Ph.D. in Neuroscience from the University of Patras and a Business Essentials Certificate from The Wharton School.